PT1260582E - Conjugados de factor ix e um polimero biocompativel - Google Patents

Conjugados de factor ix e um polimero biocompativel

Info

Publication number
PT1260582E
PT1260582E PT02013607T PT02013607T PT1260582E PT 1260582 E PT1260582 E PT 1260582E PT 02013607 T PT02013607 T PT 02013607T PT 02013607 T PT02013607 T PT 02013607T PT 1260582 E PT1260582 E PT 1260582E
Authority
PT
Portugal
Prior art keywords
factor
biocompatible polymer
conjugates
relates
factor conjugates
Prior art date
Application number
PT02013607T
Other languages
English (en)
Inventor
Eva Akerblom
Helena Sandberg
Roestin Johanna
Smeds Anna-Lisa
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20399642&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1260582(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Publication of PT1260582E publication Critical patent/PT1260582E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/813—Carrier is a saccharide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
    • Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
    • Y10S530/815—Carrier is a synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Polyamides (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PT02013607T 1995-09-29 1996-09-27 Conjugados de factor ix e um polimero biocompativel PT1260582E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9503380A SE9503380D0 (sv) 1995-09-29 1995-09-29 Protein derivatives

Publications (1)

Publication Number Publication Date
PT1260582E true PT1260582E (pt) 2005-03-31

Family

ID=20399642

Family Applications (3)

Application Number Title Priority Date Filing Date
PT96932915T PT871649E (pt) 1995-09-29 1996-09-27 Conjugados de um polipeptideo e de um polimero biocompativel
PT02013613T PT1258497E (pt) 1995-09-29 1996-09-27 Conjugados de factor viii e um polimero biocompativel
PT02013607T PT1260582E (pt) 1995-09-29 1996-09-27 Conjugados de factor ix e um polimero biocompativel

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PT96932915T PT871649E (pt) 1995-09-29 1996-09-27 Conjugados de um polipeptideo e de um polimero biocompativel
PT02013613T PT1258497E (pt) 1995-09-29 1996-09-27 Conjugados de factor viii e um polimero biocompativel

Country Status (18)

Country Link
US (1) US6048720A (pt)
EP (3) EP0871649B1 (pt)
JP (1) JP3911023B2 (pt)
AT (3) ATE283351T1 (pt)
AU (1) AU706246B2 (pt)
BR (1) BR9610695A (pt)
CA (1) CA2231801C (pt)
DE (3) DE69634373T2 (pt)
DK (3) DK0871649T3 (pt)
ES (3) ES2187676T3 (pt)
HU (1) HU221208B1 (pt)
NO (2) NO321096B1 (pt)
NZ (1) NZ319322A (pt)
PL (1) PL185821B1 (pt)
PT (3) PT871649E (pt)
SE (1) SE9503380D0 (pt)
WO (1) WO1997011957A1 (pt)
ZA (1) ZA968139B (pt)

Families Citing this family (171)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT405740B (de) * 1996-12-13 1999-11-25 Immuno Ag Von willebrand-faktor-derivat sowie ein verfahren zur isolierung von proteinen
SK286217B6 (sk) * 1998-04-28 2008-05-06 Laboratoires Serono Sa Polyol-interferón-ß konjugát, spôsob jeho výroby a farmaceutický prostriedok s jeho obsahom
US7425541B2 (en) * 1998-12-11 2008-09-16 Medarex, Inc. Enzyme-cleavable prodrug compounds
PL198123B1 (pl) 1999-02-22 2008-05-30 Baxter Int Kompozycja czynnika VIII bez dodatku albuminy i jej zastosowanie
US6635676B2 (en) * 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US7655252B2 (en) 1999-04-28 2010-02-02 The Regents Of The University Of Michigan Antimicrobial nanoemulsion compositions and methods
IT1318484B1 (it) * 2000-04-21 2003-08-25 Univ Roma Derivati di colina per il trattamento della malattia di alzheimer.
US7160540B2 (en) 2000-06-30 2007-01-09 Regents Of The University Of Minnesota Methods for detecting activity of clottings factors
US6423826B1 (en) 2000-06-30 2002-07-23 Regents Of The University Of Minnesota High molecular weight derivatives of vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US20020120109A1 (en) * 2000-07-07 2002-08-29 Samokhin Gennady P. Biologically active proteins
AU2002225681A1 (en) * 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
JP2010209109A (ja) * 2001-06-25 2010-09-24 Regents Of The Univ Of Michigan 抗微生物ナノエマルジョンの組成物および方法
CA2452582C (en) * 2001-07-11 2013-01-22 Maxygen Holdings, Ltd. G-csf conjugates
US7214660B2 (en) * 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
CN102180944A (zh) * 2001-10-10 2011-09-14 诺和诺德公司 肽的重构和糖缀合
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
SE0104186D0 (sv) * 2001-12-12 2001-12-12 Darcy Birse Method and device
ME00239B (me) * 2002-01-18 2011-05-10 Biogen Ma Inc Polimerna jedinjenja polialkilena i njihova upotreba
US20030149246A1 (en) * 2002-02-01 2003-08-07 Russell John C. Macromolecular conjugates and processes for preparing the same
AU2003227028A1 (en) * 2002-03-02 2003-09-16 F. Hoffmann-La Roche Ag Conjugates of the c domain of human gelatinase a and polyethylene glycol, methods of purification and uses thereof
DE60336555D1 (de) 2002-06-21 2011-05-12 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
PT1545613E (pt) * 2002-07-31 2011-09-27 Seattle Genetics Inc Conjugados de auristatina e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infecciosa
LT1596887T (lt) * 2003-02-26 2022-04-25 Nektar Therapeutics Polimero-faktoriaus viii fragmento konjugatai
WO2004103270A2 (en) * 2003-04-02 2004-12-02 Suntory Pharmaceutical Research Laboratories Llc Compounds and methods for treatment of thrombosis
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
EP2338333B1 (en) 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylation methods and proteins/peptides produced by the methods
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DE602004028725D1 (de) * 2003-05-12 2010-09-30 Affymax Inc Neue poly(ethylenglycol) modifizierte erythropoietinagonisten und deren verwendungen
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
LT2644206T (lt) * 2003-05-23 2019-05-27 Nektar Therapeutics Peg dariniai, susidedantys iš dviejų peg grandinių
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
AU2004316290C1 (en) * 2003-11-06 2012-02-02 Seagen Inc. Monomethylvaline compounds capable of conjugation to ligands
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
CA2549413A1 (en) * 2003-12-03 2005-06-23 Neose Technologies, Inc. Glycopegylated factor ix
US20050171002A1 (en) * 2004-02-03 2005-08-04 Mohanty Dillip K. Polyoxyalkylene compound and method for making
AU2005228945B2 (en) 2004-03-19 2010-09-30 Baxter Healthcare S.A. Factor IXa for the treatment of bleeding disorders
CA2568388A1 (en) * 2004-06-08 2005-12-29 Alza Corporation Preparation of macromolecular conjugates by four-component condensation reaction
AU2014280936B2 (en) * 2004-06-30 2016-12-15 Nektar Therapeutics Polymer-factor ix moiety conjugates
AU2005260763B2 (en) * 2004-06-30 2011-12-22 Nektar Therapeutics Polymer-factor IX moiety conjugates
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
AU2005292135B2 (en) * 2004-09-29 2011-09-29 The Administrators Of The Tulane Educational Fund Inhibitors of hepatitits C virus
CA2585758C (en) 2004-10-29 2017-08-01 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
AU2013203348B2 (en) * 2004-11-12 2016-03-03 Bayer Healthcare Llc Site-directed modification of FVIII
AU2012203813B2 (en) * 2004-11-12 2013-10-24 Bayer Healthcare Llc Site-directed modification of FVIII
EP1817336B1 (en) * 2004-11-12 2019-01-09 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
NO345800B1 (no) 2004-11-12 2021-08-09 Bayer Healthcare Llc Isolert konjugat omfattende full-lengde faktor VIII kovalent festet ved B-domenet til en eller flere biokompatible polymerer, farmasøytisk sammensetning og anvendelse for behandling av hemofili.
AU2016203693B2 (en) * 2004-11-12 2018-08-23 Bayer Healthcare Llc Site-directed modification of FVIII
PL1835938T3 (pl) 2004-12-27 2014-01-31 Baxalta Inc Koniugaty polimer-czynnik von Willebrandta
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
US20080207505A1 (en) * 2005-01-12 2008-08-28 James Kenneth D Bna Conjugates and Methods of Use
WO2006121569A2 (en) * 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
EP2975135A1 (en) 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
WO2007008848A2 (en) * 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
ES2585357T3 (es) 2005-07-07 2016-10-05 Seattle Genetics, Inc. Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
US7395967B2 (en) * 2005-07-21 2008-07-08 University Of Washington Methods and systems for counterbalancing a scanning beam device
US20070105755A1 (en) * 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP1816201A1 (en) 2006-02-06 2007-08-08 CSL Behring GmbH Modified coagulation factor VIIa with extended half-life
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
CA2647314A1 (en) 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
US7982010B2 (en) * 2006-03-31 2011-07-19 Baxter International Inc. Factor VIII polymer conjugates
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
US7985839B2 (en) * 2006-03-31 2011-07-26 Baxter International Inc. Factor VIII polymer conjugates
JP2009544327A (ja) 2006-07-21 2009-12-17 ノヴォ ノルディスク アー／エス Ｏ−結合型グリコシル化配列によるペプチドのグリコシル化
US8969532B2 (en) * 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
LT2068907T (lt) * 2006-10-04 2018-01-10 Novo Nordisk A/S Glicerolio sujungti pegilinti sacharidai ir glikopeptidai
PL2101821T3 (pl) 2006-12-15 2015-01-30 Baxalta Inc Koniugat czynnik viia-(poli)kwas sjalowy o przedłużonym okresie półtrwania in vivo
CA2673459C (en) 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
WO2008082613A2 (en) * 2006-12-27 2008-07-10 Nektar Therapeutics Al, Corporation Factor ix moiety-polymer conjugates having a releasable linkage
WO2008082669A2 (en) * 2006-12-27 2008-07-10 Nektar Therapeutics Al, Corporation Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage
AU2008237411B2 (en) 2007-04-03 2013-10-03 Ratiopharm Gmbh Methods of treatment using glycopegylated G-CSF
EP2150264A4 (en) * 2007-04-26 2014-09-24 Bayer Healthcare Llc STABILIZATION OF LIQUID SOLUTIONS OF A RECOMBINANT PROTEIN FOR FROZEN STORAGE
WO2008137747A1 (en) 2007-05-02 2008-11-13 The Regents Of The University Of Michigan Nanoemulsion therapeutic compositions and methods of using the same
MX2009013259A (es) 2007-06-12 2010-01-25 Novo Nordisk As Proceso mejorado para la produccion de azucares de nucleotidos.
CA2690218C (en) 2007-06-13 2017-02-28 Csl Behring Gmbh Use of vwf stabilized fviii preparations and of vwf preparations without fviii for extravascular administration in the therapy and prophylactic treatment of bleeding disorders
CL2008002085A1 (es) 2007-07-16 2008-11-21 Genentech Inc Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
ES2528922T3 (es) 2007-07-16 2015-02-13 Genentech, Inc. Anticuerpos anti-CD79b humanizados e inmunoconjugados y métodos de uso
US20090035848A1 (en) * 2007-08-03 2009-02-05 Robert Hickey Moving bed biofilm reactor (mbbr) system for conversion of syngas components to liquid products
GB2467700A (en) * 2007-11-09 2010-08-11 Baxter Int Modified recombinant Factor VIII and von Willebrand Factor and methods of use
ES2587392T3 (es) 2008-01-31 2016-10-24 Genentech, Inc. Anticuerpos anti-CD79b e inmunoconjugados y métodos de uso
DK2257311T3 (da) 2008-02-27 2014-06-30 Novo Nordisk As Konjugerede Faktor VIII-Molekyler
KR20110017420A (ko) 2008-06-04 2011-02-21 바이엘 헬스케어 엘엘씨 폰 빌레브란트 질환의 치료를 위한 ｆｖｉｉｉ 뮤테인
AU2009262476C1 (en) 2008-06-24 2016-06-02 Csl Behring Gmbh Factor VIII, von Willebrand factor or complexes thereof with prolonged in vivo half-life
JP4966434B2 (ja) * 2008-10-15 2012-07-04 バクスター・インターナショナル・インコーポレイテッド 結合抗体の存在下における組換え血液凝固因子のｐｅｇ化
JP2012508172A (ja) * 2008-11-03 2012-04-05 バイエル・ヘルスケア・エルエルシー 血友病の治療方法
CA2742328C (en) 2008-11-07 2019-02-26 Baxter International Inc. Factor viii formulations
WO2010057197A1 (en) 2008-11-17 2010-05-20 The Regents Of The University Of Michigan Cancer vaccine compositions and methods of using the same
CN117050147A (zh) 2009-02-03 2023-11-14 阿穆尼克斯制药公司 延伸重组多肽和包含该延伸重组多肽的组合物
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
TWI537006B (zh) * 2009-07-27 2016-06-11 巴克斯歐塔公司 凝血蛋白接合物
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
PT2459224T (pt) 2009-07-27 2016-09-05 Baxalta Inc Conjugados proteicos para coagulação sanguínea
BR112012004104B1 (pt) 2009-08-24 2022-01-04 Bioverativ Therapeutics Inc Proteína de fusão de fator ix e seu uso
SG10201907152YA (en) 2009-12-06 2019-09-27 Bioverativ Therapeutics Inc Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
EP3372617B1 (en) 2010-04-02 2024-07-24 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
EP2591101B1 (en) 2010-07-09 2018-11-07 Bioverativ Therapeutics Inc. Systems for factor viii processing and methods thereof
LT2591006T (lt) 2010-07-09 2019-08-26 Bioverativ Therapeutics Inc. Apdorojamos viengrandės molekulės ir iš jų gauti polipeptidai
JP2014501227A (ja) * 2010-12-16 2014-01-20 ノヴォ ノルディスク アー／エス 第ｖｉｉｉ因子水溶液
PL2654794T3 (pl) 2010-12-22 2020-07-27 Baxalta GmbH Materiały i sposoby sprzęgania rozpuszczalnej w wodzie pochodnej kwasu tłuszczowego z białkiem
HUE043894T2 (hu) 2011-06-10 2019-09-30 Bioverativ Therapeutics Inc Koagulációt elõsegítõ vegyületek és alkalmazásuk módszerei
RS58578B1 (sr) 2011-07-08 2019-05-31 Bioverativ Therapeutics Inc Faktor viii himernih i hibridnih polipeptida i postupci za njihovu upotrebu
EP2737311B1 (en) 2011-07-25 2020-12-02 Bioverativ Therapeutics Inc. Assays to monitor bleeding disorders
ES2700583T3 (es) 2012-01-12 2019-02-18 Bioverativ Therapeutics Inc Procedimientos para reducir la inmunogenicidad contra el Factor VIII en individuos sometidos a terapia con Factor VIII
JP6255630B2 (ja) 2012-01-12 2018-01-10 バイオベラティブ セラピューティクス インコーポレイテッド キメラ第ｖｉｉｉ因子ポリペプチドおよびその使用
PL2814502T3 (pl) 2012-02-15 2018-02-28 Csl Behring Gmbh Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII
CA2864126A1 (en) 2012-02-15 2013-08-22 Biogen Idec Ma Inc. Recombinant factor viii proteins
LT2814840T (lt) 2012-02-15 2020-02-25 Bioverativ Therapeutics Inc. Faktoriaus viii kompozicijos ir jų gavimo ir naudojimo būdai
AU2013226090B2 (en) 2012-02-27 2018-03-08 Amunix Operating Inc. XTEN conjugate compositions and methods of making same
GEP201706716B (en) * 2012-04-16 2017-08-10 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
US20150080309A1 (en) 2012-04-24 2015-03-19 Nova Nordisk A/S Compounds Suitable for Treatment of Haemophilia
EP4079316A1 (en) 2012-06-08 2022-10-26 Bioverativ Therapeutics Inc. Procoagulant compounds
AU2013270683A1 (en) 2012-06-08 2014-12-11 Biogen Ma Inc. Chimeric clotting factors
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
JP6603128B2 (ja) 2012-07-11 2019-11-06 バイオベラティブ セラピューティクス インコーポレイテッド ＸＴＥＮおよびｖｏｎＷｉｌｌｅｂｒａｎｄ因子タンパク質を有する第ＶＩＩＩ因子の複合体、および、その使用
EP3970738A1 (en) 2012-07-25 2022-03-23 Bioverativ Therapeutics Inc. Blood factor monitoring assay and uses thereof
AU2013331000B2 (en) 2012-10-18 2018-04-19 Bioverativ Therapeutics Inc. Methods of using a fixed dose of a clotting factor
EP2914293A4 (en) 2012-10-30 2016-04-20 Biogen Ma Inc METHOD OF USE OF FVIII POLYPEPTIDE
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
HRP20231183T1 (hr) 2013-02-15 2024-01-05 Bioverativ Therapeutics Inc. Optimizirani gen faktora viii
ES2926798T3 (es) 2013-03-15 2022-10-28 Bioverativ Therapeutics Inc Formulaciones de polipéptido de factor VIII
CA2899089C (en) 2013-03-15 2021-10-26 Biogen Ma Inc. Factor ix polypeptide formulations
EP2796145B1 (en) 2013-04-22 2017-11-01 CSL Ltd. A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge
KR20240023705A (ko) 2013-06-28 2024-02-22 바이오버라티브 테라퓨틱스 인크. Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도
US10947269B2 (en) 2013-08-08 2021-03-16 Bioverativ Therapeutics Inc. Purification of chimeric FVIII molecules
EP3033097B1 (en) 2013-08-14 2021-03-10 Bioverativ Therapeutics Inc. Factor viii-xten fusions and uses thereof
EP3065769A4 (en) 2013-11-08 2017-05-31 Biogen MA Inc. Procoagulant fusion compound
EP4332839A3 (en) 2013-12-06 2024-06-05 Bioverativ Therapeutics Inc. Population pharmacokinetics tools and uses thereof
PT3091997T (pt) 2014-01-10 2022-09-29 Bioverativ Therapeutics Inc Proteínas quiméricas de fator viii e utilizações destas
KR102382402B1 (ko) 2014-02-04 2022-04-01 바이오젠 엠에이 인코포레이티드 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도
PT3122757T (pt) 2014-02-28 2023-11-03 Hangzhou Dac Biotech Co Ltd Ligantes carregados e as suas utilizações em conjugação
BR112016030950A2 (pt) 2014-07-02 2018-03-27 Csl Ltd polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.
PT3262071T (pt) 2014-09-23 2020-06-16 H Hoffnabb La Roche Ag Métodos de utilização de imunoconjugados anti-cd79b
MA40864A (fr) 2014-10-31 2017-09-05 Biogen Ma Inc Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
WO2016142288A1 (en) 2015-03-06 2016-09-15 Csl Behring Recombinant Facility Ag Modified von willebrand factor having improved half-life
ES2912300T3 (es) 2015-05-22 2022-05-25 CSL Behring Lengnau AG Procedimientos de preparación de factor von Willebrand modificado
SG10201910896UA (en) 2015-05-22 2020-01-30 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
JP6759326B2 (ja) 2015-07-12 2020-09-23 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 細胞結合分子の共役のための架橋連結体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
IL257231B (en) 2015-08-03 2022-09-01 Bioverativ Therapeutics Inc Factor ix fusion proteins and methods for their preparation and use
US10189888B2 (en) 2015-11-13 2019-01-29 Baxalta Incorporated Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
EA202092049A1 (ru) 2015-11-13 2020-11-10 Баксалта Инкорпорейтед Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
KR20180098404A (ko) 2016-01-07 2018-09-03 체에스엘 베링 리컴비넌트 퍼실리티 아게 돌연변이된 폰 빌레브란트 인자
ES2909573T3 (es) 2016-01-07 2022-05-09 CSL Behring Lengnau AG Factor de von Willebrand truncado mutado
HUE059941T2 (hu) 2016-02-01 2023-01-28 Bioverativ Therapeutics Inc Optimalizált VIII-as faktor gének
EP3476937A4 (en) 2016-06-24 2019-12-04 Mogam Institute for Biomedical Research CHIMERIC PROTEIN WITH FVIII AND VWF FACTORS AND USE THEREOF
TW201828974A (zh) 2016-11-11 2018-08-16 瑞士商Ｃｓｌ貝林重組技能公司 用於血管外施予以治療或預防凝血疾病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類
SG10201912360SA (en) 2016-11-11 2020-02-27 CSL Behring Lengnau AG Truncated von willebrand factor polypeptides for treating hemophilia
JP7138350B2 (ja) 2016-11-14 2022-09-16 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ． 共役連結体、該連結体を含有する細胞結合分子－薬物共役体、並びに該共役体及び連結体の使用及び製造方法
IL308416A (en) 2016-12-02 2024-01-01 Bioverativ Therapeutics Inc Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
US20200085915A1 (en) 2016-12-02 2020-03-19 Bioverativ Therapeutics Inc. Methods of inducing immune tolerance to clotting factors
JP7374883B2 (ja) 2017-08-09 2023-11-07 バイオベラティブ セラピューティクス インコーポレイテッド 核酸分子およびその使用
WO2019152692A1 (en) 2018-02-01 2019-08-08 Bioverativ Therapeutics, Inc. Use of lentiviral vectors expressing factor viii
CA3096038A1 (en) 2018-04-04 2019-10-10 Sigilon Therapeutics, Inc. Implantable particles and related methods
SG11202010767SA (en) 2018-05-18 2020-11-27 Bioverativ Therapeutics Inc Methods of treating hemophilia a
EP3823985A1 (en) 2018-07-16 2021-05-26 Baxalta Incorporated Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
KR20210042128A (ko) 2018-08-09 2021-04-16 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도
UY38389A (es) 2018-09-27 2020-04-30 Sigilon Therapeutics Inc Dispositivos implantables para terapia celular y métodos relacionados
BR112021013874A2 (pt) 2019-01-16 2021-09-21 Baxalta Incorporated Composição de ácido nucleico, vetor de terapia de gene de mamífero, partícula de vírus adeno-associado, métodos para tratar hemofilia a e para produzir uma partícula de vírus adeno-associado, e, uso de uma composição de ácido nucleico e de um vetor de terapia de gene de mamífero
CA3144630A1 (en) 2019-06-19 2020-12-24 Bioverativ Therapeutics Inc. Methods and compositions for treating hemophilia and low bone mineral density with factor viiifc protein
EP4073106A2 (en) 2019-12-12 2022-10-19 Takeda Pharmaceutical Company Limited Gene therapy of hemophilia a using viral vectors encoding recombinant fviii variants with increased expression
CN117858895A (zh) 2021-06-14 2024-04-09 武田药品工业株式会社 使用表达增强的编码重组fviii变体的病毒载体的血友病a基因疗法
TW202323274A (zh) 2021-08-23 2023-06-16 美商百歐維拉提夫治療公司 優化因子viii基因
AU2022355088A1 (en) 2021-09-30 2024-05-16 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity
WO2024081309A1 (en) 2022-10-11 2024-04-18 Sigilon Therapeutics, Inc. Engineered cells and implantable elements for treatment of disease

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59172425A (ja) * 1983-03-18 1984-09-29 Nippon Chemiphar Co Ltd 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
SE8501050D0 (sv) * 1985-03-05 1985-03-05 Kabivitrum Ab Biologically active fragments of human antihemophilic factor and method for preparation thereof
DE3717210C2 (de) * 1987-05-22 1993-11-25 Diagen Inst Molekularbio Verfahren zur Modifizierung von Nukleinsäuren
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
JPH06506217A (ja) * 1991-03-18 1994-07-14 エンゾン，インコーポレーテッド ポリペプチドまたはグリコポリペプチドとポリマーとのヒドラジン含有結合体
US5169627A (en) * 1991-10-28 1992-12-08 Mount Sinai School Of Medicine Of The City University Of New York Oral pharmaceutical composition containing a polyethylene glycol-immunoglobulin G conjugate for reconstitution of secretory immunity and method of reconstituting secretory immunity
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
WO1994015625A1 (en) * 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates

Also Published As

Publication number Publication date
ATE289321T1 (de) 2005-03-15
NZ319322A (en) 1998-08-26
PT1258497E (pt) 2005-06-30
NO20051950L (no) 1998-03-27
PL185821B1 (pl) 2003-08-29
PL325958A1 (en) 1998-08-17
DK0871649T3 (da) 2003-03-24
HUP9901203A2 (hu) 1999-07-28
ES2187676T3 (es) 2003-06-16
DE69633952T2 (de) 2006-03-02
ES2238522T3 (es) 2005-09-01
AU7151796A (en) 1997-04-17
PT871649E (pt) 2003-04-30
ES2236396T3 (es) 2005-07-16
EP1258497B1 (en) 2005-02-16
DE69625085T2 (de) 2003-07-17
NO981408D0 (no) 1998-03-27
DE69634373T2 (de) 2005-12-29
DE69625085D1 (de) 2003-01-09
NO321096B1 (no) 2006-03-13
DK1258497T3 (da) 2005-06-06
AU706246B2 (en) 1999-06-10
EP1258497A3 (en) 2002-11-27
EP0871649A1 (en) 1998-10-21
CA2231801C (en) 2010-07-27
EP1260582B1 (en) 2004-11-24
BR9610695A (pt) 1999-07-06
EP1258497A2 (en) 2002-11-20
ATE283351T1 (de) 2004-12-15
JP3911023B2 (ja) 2007-05-09
EP1260582A1 (en) 2002-11-27
DK1260582T3 (da) 2005-03-29
ZA968139B (en) 1997-05-29
HUP9901203A3 (en) 2000-02-28
CA2231801A1 (en) 1997-04-03
HU221208B1 (en) 2002-08-28
NO981408L (no) 1998-03-27
JPH11513378A (ja) 1999-11-16
SE9503380D0 (sv) 1995-09-29
DE69634373D1 (de) 2005-03-24
EP0871649B1 (en) 2002-11-27
ATE228531T1 (de) 2002-12-15
WO1997011957A1 (en) 1997-04-03
DE69633952D1 (de) 2004-12-30
US6048720A (en) 2000-04-11

Similar Documents

Publication Publication Date Title
PT871649E (pt) Conjugados de um polipeptideo e de um polimero biocompativel
ATE236656T1 (de) Eingeschränktes multifunktionelles reagens zur oberflächenmodifikation
CA2150925A1 (en) Improved synthesis of polymer bio-active conjugates
AU645747B2 (en) A novel antibody delivery system for biological response modifiers
FI955320A0 (fi) Bioaktiivisia ja/tai kohdennettuja dendriimikonjugaatteja
AU7366687A (en) Coupling agents for radiolabeling proteins
EA200001111A1 (ru) КОНЪЮГАТЫ ПОЛИОЛ-β-ИНТЕРФЕРОН
DE59611341D1 (de) Verwendung von saccharid-konjugaten
DE50014571D1 (de) Träger-pharmaka-konjugate
BR9509001A (pt) Proteína que objetiva virions de HIV com base em moléculas de fusão HIV-1 VPR
WO1993020852A3 (en) Macrocyclic chelating agents, chelates and conjugates thereof
AU2979195A (en) Conjugates made of metal complexes and oligonucleotides
RU93055877A (ru) Вещество усиливающее экскрецию желчной кислоты
ES1026348U (es) Grapilla/abrazadera, para montaje de componentes de lamparas o analogos.
ES1022847U (es) Soporte publicitario adaptable a vehiculos con ruedas.